Vyleesi International Purchase Legalities: What You Need to Know in 2026

Is It Legal to Buy Vyleesi Outside the United States?

Buying Vyleesi from a foreign pharmacy and importing it into the United States is not legal in most circumstances. The FDA has not approved any foreign-manufactured version of bremelanotide, and the drug is not commercially available in any other country, which closes the door on the narrow personal-import exceptions that sometimes apply to other medications.

The FDA's Personal Importation Policy

The FDA's personal-importation guidance allows agents to exercise "enforcement discretion" for a 90-day supply of a foreign drug under specific conditions: the drug must be for personal use, it must not pose an unreasonable risk, and it must generally be unavailable in the United States. FDA Personal Importation Policy.

Vyleesi fails that last test. It is commercially available domestically. That single fact means the enforcement-discretion exception almost certainly does not apply. A package arriving from overseas could be seized by U.S. Customs and Border Protection regardless of the quantity inside.

Why No Approved International Version Exists

Bremelanotide was developed by Palatin Technologies and licensed to AMAG Pharmaceuticals for the U.S. Market. As of 2026, no marketing authorization application has been approved by the European Medicines Agency, Health Canada, the UK Medicines and Healthcare products Regulatory Agency, or the Therapeutic Goods Administration in Australia. Without an approved product, there is no legitimate foreign supply chain. Any website claiming to sell genuine Vyleesi from a Canadian or European pharmacy is misrepresenting its product.

What Happens at the Border

U.S. Customs and Border Protection and the FDA work jointly on mail-order pharmaceutical interceptions. Packages are routinely flagged, opened, and tested. If bremelanotide is identified, the shipment is seized and the importer may receive a Warning Letter. Repeat violations can escalate. The financial loss falls entirely on the buyer because payment processors rarely reverse charges for illegal imports.

The Counterfeit Risk Is Substantial

Online pharmacies operating outside regulated markets frequently sell peptide analogs or entirely different compounds labeled as bremelanotide. The FDA's Office of Criminal Investigations has documented repeated cases of misrepresented injectable peptides that contained bacterial endotoxins, incorrect concentrations, or no active ingredient at all. FDA Warning on Counterfeit Drugs.

Peptide Research-Chemical Sites

A subset of websites sells bremelanotide as a "research chemical" not for human use. This is a legal disclaimer that does not protect buyers from federal law. Injecting an unverified peptide compound carries direct health risks:

• Bacterial contamination from non-sterile manufacturing
• Undisclosed excipients causing allergic reactions
• Incorrect pH leading to injection-site necrosis
• Incorrect dosing leading to acute blood pressure spikes, which the FDA identified as the primary safety concern in the Phase 3 trials for the approved product [1]

The Phase 3 RECONNECT trials (N=1,267 in Study 1; N=1,279 in Study 2) that supported FDA approval used pharmaceutical-grade bremelanotide manufactured under current Good Manufacturing Practice. Researchers found that 40.4% of women on bremelanotide reported nausea and a transient mean maximum systolic blood pressure increase of approximately 6 mmHg versus placebo [1]. Off-label, unverified product could produce unpredictable cardiovascular responses.

How Vyleesi Is Priced in the U.S. And Why It Feels Inaccessible

The 2026 wholesale acquisition cost for a 4-injection carton of Vyleesi is approximately $1,000. Most commercial insurance plans classify bremelanotide as a non-essential or lifestyle drug and either exclude it entirely or place it on a high-cost specialty tier. That pricing gap is what drives patients toward international sources, but the legal and safety exposure from those sources is disproportionate.

Insurance Coverage Field

Coverage varies significantly by plan. Some plans that cover HSDD pharmacotherapy under a mental-health or women's-health benefit will approve bremelanotide after a prior authorization. The process typically requires:

1. A documented HSDD diagnosis using validated screening (e.g., Female Sexual Distress Scale-Revised score of 11 or above)
2. Confirmation of premenopausal status
3. Absence of contraindications (uncontrolled hypertension, cardiovascular disease, use of naltrexone or other CNS opioid-active agents)

Appealing a denial is worthwhile. Roughly 40% of specialty drug appeals succeed when supported by a letter of medical necessity from the prescribing clinician.

The Role of Flibanserin as a Comparator

Some insurers will cover flibanserin (Addyi), the other FDA-approved HSDD medication, more readily because it carries a lower list price and has been on formulary longer. Clinicians sometimes use a flibanserin trial as a stepping stone to obtain bremelanotide coverage. The two drugs have different mechanisms: flibanserin is a serotonin 1A agonist and 2A antagonist taken daily, while bremelanotide is a melanocortin receptor agonist used on demand [2]. Neither is superior across all patients, and individual response is the deciding factor.

Legitimate Ways to Reduce Vyleesi Cost

There are several domestic options that meaningfully reduce out-of-pocket cost without legal risk.

Manufacturer Savings Card

Palatin Technologies has maintained a savings card program through its commercial partner. Eligible patients with commercial (non-government) insurance may pay as little as $0 to $99 per fill. The program is income-independent but explicitly excludes Medicare, Medicaid, and other federal health program beneficiaries. Patients should verify current program terms directly at the manufacturer's patient support site because savings programs change annually.

Patient Assistance Program

For patients who are uninsured or underinsured and meet income thresholds, a Patient Assistance Program (PAP) can provide Vyleesi at no cost. The application requires proof of income, a prescription, and completion of enrollment forms. Processing takes two to four weeks on average.

GoodRx and Pharmacy Discount Cards

GoodRx and similar discount platforms negotiate cash prices with retail pharmacies. Prices vary considerably by pharmacy and ZIP code. In 2025 data, GoodRx showed cash prices ranging from roughly $700 to $900 for a 4-injection carton at major retail chains. That is still high, but it is a legitimate option for patients who are between insurance plans.

Telehealth Platforms and Bundled Pricing

Some telehealth platforms that specialize in women's sexual health include Vyleesi in a bundled consultation-plus-medication fee. These are U.S.-licensed pharmacies operating under state board of pharmacy oversight. Medication dispensed through these channels is the same FDA-approved product that would come from a retail pharmacy.

The HealthRX clinical team uses the following decision framework when evaluating Vyleesi access for patients:

Step 1. Confirm HSDD diagnosis with validated tool (FSDS-R score 11+) and premenopausal status. Step 2. Submit prior authorization to commercial insurer with letter of medical necessity. Step 3. If denied, apply manufacturer savings card (commercial insurance) or PAP (uninsured). Step 4. If savings card is not applicable (government insurer), compare GoodRx cash price versus flibanserin as formulary alternative. Step 5. If cost remains prohibitive, reassess with clinician whether off-label low-dose daily flibanserin or behavioral/sex-therapy referral addresses the underlying FSAD component.

This framework keeps the patient on an approved, trackable medication supply with documented clinical rationale at every step.

HSA and FSA Eligibility for Vyleesi

Vyleesi is eligible for purchase with Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. The IRS defines eligible medical expenses as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease IRS Publication 502. Prescription medications prescribed by a licensed clinician qualify under that definition.

What You Need

• A valid prescription from a licensed U.S. Clinician
• An HSA or FSA debit card, or itemized receipt for reimbursement
• The pharmacy must code the transaction as a prescription drug purchase (not a supply or device)

What to Watch For

FSA funds are typically use-it-or-lose-it by December 31 (with a grace period or $640 rollover in some plans as of 2026). HSA funds roll over indefinitely. Patients with a Limited-Purpose FSA tied to a High-Deductible Health Plan should verify that prescription drugs are covered under their specific plan design, because some limited-purpose FSAs restrict spending to dental and vision until a deductible is met.

Regulatory Status in Key International Markets

Because patients frequently ask whether they can obtain Vyleesi while traveling or relocate to a country where it is available, a country-by-country summary is useful.

European Union

The European Medicines Agency has not received or approved a Marketing Authorization Application for bremelanotide as of 2026. No EU member state has granted national authorization. Possession for personal use in most EU countries is not automatically criminal, but there is no legal supply chain, meaning any product labeled as bremelanotide sold in the EU is unapproved and potentially counterfeit.

Canada

Health Canada has not approved bremelanotide. The Special Access Program (SAP) theoretically allows Canadian physicians to request unapproved drugs for patients with serious conditions when no alternatives exist. HSDD, while clinically significant, has generally not met the SAP threshold of life-threatening conditions, and flibanserin (approved in Canada as Addyi in 2018) provides an alternative. A Canadian physician applying through SAP for bremelanotide would face a high bar.

United Kingdom

The MHRA has not approved bremelanotide. The UK's Medicines and Healthcare products Regulatory Agency runs a named-patient or specials scheme similar to the SAP, but the same practical barriers apply.

Australia

The TGA has not approved bremelanotide. Australia's Special Access Scheme (Category B) allows licensed practitioners to apply for unapproved medicines. The application burden and the availability of behavioral and pharmacological alternatives make approval unlikely for HSDD specifically.

Japan

The Pharmaceuticals and Medical Devices Agency (PMDA) has not approved bremelanotide. Japan's regulatory pathway for sexual dysfunction drugs has historically been cautious, and no applications appear to be pending.

The Science Behind Bremelanotide: Why It Matters for Access Decisions

Understanding what bremelanotide actually does helps clarify why quality and dose precision are non-negotiable, and why unverified compound sources are particularly dangerous.

Mechanism of Action

Bremelanotide is a cyclic heptapeptide that acts as a non-selective agonist of melanocortin receptors, primarily MC1R, MC3R, MC4R, and MC5R [2]. Its effects on sexual desire are thought to be mediated primarily through central MC4R activation in hypothalamic and limbic regions. This same receptor pathway also influences blood pressure regulation, which explains the transient hypertension side effect observed in trials.

Phase 3 Efficacy Data

The RECONNECT program included two Phase 3 randomized controlled trials. In Study 1 (N=1,267), women using bremelanotide 1.75 mg reported a statistically significant increase in satisfying sexual events versus placebo (P<0.001) and a significant reduction in distress as measured by the FSDS-R desire domain score [1]. The effect size was modest. The drug increased satisfying sexual events by approximately 0.5 events per month over placebo. The FDA considered this clinically meaningful for a condition with no other on-demand pharmacological option at the time of approval. FDA Prescribing Information for Vyleesi.

The 1.75 mg Dose Is Specific

Research-chemical bremelanotide is sold in vials of 2 mg, 5 mg, and 10 mg with instructions for self-reconstitution, which introduces compounding error. The approved product uses a fixed 1.75 mg auto-injector cartridge that delivers a precise subcutaneous dose. Dose escalation above 1.75 mg has not been approved and was associated with more frequent nausea and larger blood pressure excursions in Phase 2 dose-finding work [1].

What Telehealth Prescribers Can and Cannot Do

U.S.-based telehealth platforms can legally prescribe Vyleesi if the clinician is licensed in the patient's state and a proper clinical evaluation is completed. They cannot prescribe it to patients located outside the United States, and they cannot support importation from foreign pharmacies.

Ryan Haight Act Compliance

The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person medical evaluation before Schedule III-V controlled substances can be prescribed via telemedicine. Bremelanotide is not a controlled substance, so this restriction does not apply. Telehealth HSDD consultations using audio-video visits are legally valid in all U.S. States.

What a Proper Telehealth Evaluation Should Include

• Review of cardiovascular history and baseline blood pressure (contraindicated if uncontrolled hypertension)
• Medication reconciliation (contraindicated with naltrexone, opioid agonists; use caution with medications that slow gastric emptying)
• Validated HSDD screening using FSDS-R or BISF-W
• Discussion of realistic expectations: the modest 0.5 additional satisfying sexual events per month seen in RECONNECT trials [1]
• Instructions on the 45-minute pre-activity injection window and the limit of one dose per 24-hour period

Key Takeaways for Patients Considering International Purchase

The international purchase question usually starts with sticker shock. The legal and safety reasons not to pursue foreign sources are real, not theoretical. But there are domestic options that materially reduce cost, and a systematic approach through manufacturer programs, HSA/FSA funds, and telehealth access channels gets most commercially insured patients to an out-of-pocket cost well below the $1,000 list price.

Patients who are on Medicare or Medicaid will have a harder path because manufacturer savings cards exclude federal program beneficiaries. For those patients, the clinical conversation should honestly address whether flibanserin (which has similar modest efficacy data), sex therapy, or a combination approach better fits the financial reality.

The FDA's MedWatch program accepts reports of suspected counterfeit drugs, and patients who have received a suspicious product can file a report online. Reporting helps the agency identify patterns in illegitimate supply chains.

For any patient whose out-of-pocket cost remains above $200 per fill after exhausting manufacturer and HSA/FSA options, a direct call to the Palatin patient support line to verify current PAP income thresholds is the next concrete step.